Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
US10221245B2 · kind B2 · utility
14Cited by
55References
67Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 15, 2014 |
| Grant date | Mar 5, 2019 |
| Priority date | — |
| Expiry date | Apr 23, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides compositions and methods for treating diseases associated with expression of CD19. The invention also relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD19 binding domain.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.